Certara's fundamental outlook is challenged by a sharp revenue deceleration to -10.8% YoY in 2026Q2 and an EPS miss of -$0.36, alongside SG&A escalation that outpaced the top line. However, the asset-light model (CapEx averaging 5.8% of revenue) and cumulative...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.08-10.4% vs $0.09 | $93M-4.9% vs $98M |
Q2 2026 May 11, 2026 | $0.09-18.2% vs $0.11 | $107M+0.7% vs $106M |
Q1 2026 Feb 26, 2026 | $0.09-18.2% vs $0.11 | $104M+0.5% vs $103M |
Q4 2025 Nov 6, 2025 | $0.14+27.3% vs $0.11 | $105M+1.3% vs $103M |
Certara (NASDAQ: CERT - Get Free Report) and OneMedNet (NASDAQ: ONMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability. Volatility and Risk Certara has a beta of 1.4,
Bank of New York Mellon Corp purchased a new position in Certara, Inc. (NASDAQ: CERT) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 731,012 shares of the company's stock, valued at approximately $4,788,000. Bank of New York Mellon Corp
AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry's data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day.
Definitive Healthcare (NASDAQ: DH - Get Free Report) and Certara (NASDAQ: CERT - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, institutional ownership and valuation. Insider and Institutional Ownership 98.7% of Definitive Healthcare
Benchmark CERT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Certara, Inc. (CERT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.83 | $1.37B | -883.00 | 8.75% | -0.38% | -0.15% | — | |
| $630.19 | $17.59B | 41.24 | 19.97% | 17.67% | 110.15% | — | |
| $270.09 | $44.46B | 34.45 | 5.87% | 8.1% | 21.51% | — | |
| $285.11 | $13.73B | -97.98 | -0.85% | -5.96% | -7.63% | — | |
| $260.91 | $42.38B | 47.96 | 16.34% | 29.34% | 14% | — | |
| $18.41 | $372.34M | -5.72 | 13.09% | 9.88% | 6.18% | — |
Certara, Inc. (CERT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Certara, Inc. (CERT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 7, 2026·SEC
Aug 4, 2026·SEC
Aug 4, 2026·SEC
Get notified when CERT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Certara, Inc. (CERT) stock FAQ — growth, dividends, profitability & financials explained
Certara, Inc. (CERT) reported $408.4M in revenue for fiscal year 2025. This represents a 149% increase from $163.7M in 2018.
Certara, Inc. (CERT) grew revenue by 8.7% over the past year. This is steady growth.
Certara, Inc. (CERT) reported a net loss of $68.4M for fiscal year 2025.
Certara, Inc. (CERT) has a return on equity (ROE) of -0.2%. Negative ROE indicates the company is unprofitable.
Certara, Inc. (CERT) generated $61.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
